Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2023 | KEYNOTE-A18: pembrolizumab with chemoradiotherapy for advanced cervical cancer

Domenica Lorusso, MD, PhD, Fondazione IRCCS National Cancer Institute of Milan, Milan, Italy, discusses the results of the global Phase III KEYNOTE-A18 (NCT04221945) trial, which assessed pembrolizumab with concurrent chemoradiotherapy for treatment of locally advanced high-risk cervical cancer. The pembrolizumab plus chemoradiotherapy arm showed a statistically significant improvement in progression-free survival (PFS) compared to the placebo plus chemoradiotherapy arm. The overall-survival (OS) data is immature, but shows a trend towards improved OS in the pembrolizumab plus chemoradiotherapy arm. This interview took place at the European Society for Medical Oncology (ESMO) 2023 Congress in Madrid, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.